Regeneron looks to expand label of Eylea HD early next year

The high-dose ver­sion of Re­gen­eron’s eye treat­ment Eylea hit its pri­ma­ry end­point in a late-stage study for mac­u­lar ede­ma fol­low­ing reti­nal vein oc­clu­sion, a com­mon …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.